Visit 1 | Visit 2 | p Value | |
---|---|---|---|
Count | 28 | – | NA |
Age (years) | 72.29 (10.02) | – | NS |
Disease Duration (years) | 6.93 (3.85) | – | NS |
Agonist present* | 14, 50% | 12, 42.9% | NS |
Dose (mg) | 585.29 (166.38) | 1102.50 (237.15) | <0.0001 |
LED (mg) | 664.23 (239.54) | 1162.11 (245.11) | <0.0001 |
UPDRS Part III | 31.86 (10.68) | 28.75 (8.36) | NS |
PDQ-39 QOL | 32.79 (17.69) | 27.69 (21.31) | <0.01 |
BDI | 12.82 (9.44) | 10.04 (8.47) | <0.01 |
Dyskinesia duration, Q32 | 0.572 | ||
0% | 19 (51.4%) | 18 (48.6%) | |
1–25% | 3 (37.5%) | 5 (62.5%) | |
26–100% | 4 (44.4%) | 5 (55.6%) | |
Dyskinesia disability, Q33 | 0.572 | ||
None | 22 (48.9%) | 23 (51.1%) | |
Mild | 2 (40.0%) | 3 (60.0%) | |
Moderate, severe | 3 (60.0%) | 2 (40.0%) | |
Dyskinesia pain, Q34 | NA† | ||
None | 26 (50.0%) | 26 (50.0%) | |
Slight | 2 (100.0%) | ||
Moderate, severe | |||
Percent of day OFF Medication, Q39 | 0.521 | ||
0% | 7 (53.8%) | 6 (46.2%) | |
1–25% | 13 (50.0%) | 13 (50.0%) | |
26–100% | 6 (40.0%) | 9 (60.0%) |
Standard deviation in parenthesis
NS, not statistically significant; NA, not applicable
*Number of records where agonist is present
†Dyskinesia Q34 has only one group at visit 1—the associated test could not be carried out.